1988
THE FREQUENCY OF EPSTEIN-BARR VIRUS INFECTION AND ASSOCIATED LYMPHOPROLIFERATIVE SYNDROME AFTER TRANSPLANTATION AND ITS MANIFESTATIONS IN CHILDREN
Ho M, Jaffe R, Miller G, Breinig M, Dummer J, Makowka L, Atchison R, Karrer F, Nalesnik M, Starzl T. THE FREQUENCY OF EPSTEIN-BARR VIRUS INFECTION AND ASSOCIATED LYMPHOPROLIFERATIVE SYNDROME AFTER TRANSPLANTATION AND ITS MANIFESTATIONS IN CHILDREN. Transplantation 1988, 45: 719-726. PMID: 2833828, PMCID: PMC2993427, DOI: 10.1097/00007890-198804000-00011.Peer-Reviewed Original ResearchConceptsLymphoproliferative syndromePrimary infectionEBV infectionTransplant recipientsEpstein-Barr virus infectionMonoclonal B-cell lymphomaPediatric liver recipientsPrimary EBV infectionPediatric transplant recipientsEpstein-Barr virusEBV nuclear antigenB-cell lymphomaLiver recipientsPediatric EBVCyclosporine monitoringEBV DNAClinical typesPediatric casesSecond syndromeVirus infectionCell lymphomaAdditional casesGreater riskInfectionNuclear antigen
1986
Progressive Epstein-Barr Virus Infection
Andiman W, Katz B, Miller G. Progressive Epstein-Barr Virus Infection. 1986, 276-286. DOI: 10.1007/978-1-4612-4958-0_33.Peer-Reviewed Original ResearchEpstein-Barr virusInfectious mononucleosisEpstein-Barr virus infectionDisorders of immunitySpectrum of diseaseEBV infectionImmunologic controlFatal syndromeVirus infectionClinical conditionsNosologic entityB cellsViral replicationInfectionMononucleosisDiseaseAbnormal degreeUnchecked proliferationImmunopathogenesisRelapsingNeoplasiaSyndromeAntigenImmunity
1985
Identification and expression of a nuclear antigen from the genomic region of the Jijoye strain of Epstein-Barr virus that is missing in its nonimmortalizing deletion mutant, P3HR-1.
Rowe D, Heston L, Metlay J, Miller G. Identification and expression of a nuclear antigen from the genomic region of the Jijoye strain of Epstein-Barr virus that is missing in its nonimmortalizing deletion mutant, P3HR-1. Proceedings Of The National Academy Of Sciences Of The United States Of America 1985, 82: 7429-7433. PMID: 2997790, PMCID: PMC391358, DOI: 10.1073/pnas.82.21.7429.Peer-Reviewed Original ResearchConceptsChronic active EBV infectionActive EBV infectionEpstein-Barr virusJijoye strainEBV infectionEBV DNACertain patientsP3HR-1Human antiseraVirus strainsNuclear antigenHr-1JijoyeVirus deletion mutantsLtk- cellsMouse Ltk- cellsImmortalization processPatientsGene transferNeoantigensLymphocytesInfectionAntigenAntibody Responses to Two Epstein-Barr Virus Nuclear Antigens Defined by Gene Transfer
Miller G, Grogan E, Fischer D, Niederman J, Schooley R, Henle W, Lenoir G, Liu C. Antibody Responses to Two Epstein-Barr Virus Nuclear Antigens Defined by Gene Transfer. New England Journal Of Medicine 1985, 312: 750-755. PMID: 2983211, DOI: 10.1056/nejm198503213121204.Peer-Reviewed Original ResearchConceptsChronic active EBV infectionActive EBV infectionEBV infectionNuclear antigenEpstein-Barr virus nuclear antigenEpstein-Barr virus DNAEBV-seropositive subjectsAbnormal immune responseAssociation of EBVNorth African patientsAbsence of antibodiesSuch patientsAfrican patientsSerologic studiesImmune responseNasopharyngeal carcinomaLymphoid cellsPatientsViral gene productsSpecific viral gene productsViral mutationsSerologic reactionsAntigenSerum samplesM antigen
1981
Genome of a mononucleosis epstein-barr virus contains DNA fragments previously regarded to be unique to Burkitt's lymphoma isolates
Fischer D, Miller G, Gradoville L, Heston L, Weststrate M, Maris W, Wright J, Brandsma J, Summers W. Genome of a mononucleosis epstein-barr virus contains DNA fragments previously regarded to be unique to Burkitt's lymphoma isolates. Cell 1981, 24: 543-553. PMID: 6263500, DOI: 10.1016/0092-8674(81)90345-7.Peer-Reviewed Original ResearchConceptsBurkitt's lymphomaB95-8Infectious mononucleosisUncomplicated infectious mononucleosisEpstein-Barr virusSalivary isolatesEBV infectionDisease manifestationsLymphomaMononucleosisPatientsEBVRestriction enzyme analysisVirusMajor insertionC fragmentEnzyme analysisHr-1IsolatesInfectionDeletionAvailable virus
1979
Experimental Carcinogenicity by the Virus In Vivo
Miller G. Experimental Carcinogenicity by the Virus In Vivo. 1979, 351-372. DOI: 10.1007/978-3-642-67236-1_16.Peer-Reviewed Original ResearchEpstein-Barr virusEBV nuclear antigenBurkitt's lymphomaEBV DNA copiesHuman EBV infectionEBV infectionLymphoid folliclesLymphoproliferative syndromeMalignant diseaseGerminal centersLymphoid neoplasmsNew World primatesNuclear antigenSpectrum of responsesOwl monkeysLymphomaInfectionExperimental carcinogenicityVirusDNA copiesNeoplasmsSyndromeTumorsAntigenDisease
1974
OROPHARYNGEAL EXCRETION OF EPSTEIN-BARR VIRUS BY PATIENTS TREATED WITH IMMUNOSUPPRESSIVE DRUGS
Siegel N, Strauch B, Andrews L, Miller G, Cook C. OROPHARYNGEAL EXCRETION OF EPSTEIN-BARR VIRUS BY PATIENTS TREATED WITH IMMUNOSUPPRESSIVE DRUGS. Pediatric Research 1974, 8: 428-428. DOI: 10.1203/00006450-197404000-00531.Peer-Reviewed Original ResearchEpstein-Barr virusRenal homograftsImmunosuppressive agentsImmunosuppressive drugsHuman umbilical cord leukocytesRenal transplant recipientsLatent EBV infectionEBV capsid antigenEBV nuclear antigenUmbilical cord leukocytesRate of excretionOropharyngeal excretionEBV infectionImmunosuppressive therapySeropositive patientsTransplant recipientsCapsid antigenThroat washingsVirus 8Chronic uremiaThroat samplesHealthy controlsPatientsExcretion rateExcretion
1972
Prospective study of Epstein-Barr virusinfections in acute lymphoblastic leukemia of childhood
Miller G, Shope T, Heston L, O'Brien R, Schwartz A, Pearson H. Prospective study of Epstein-Barr virusinfections in acute lymphoblastic leukemia of childhood. The Journal Of Pediatrics 1972, 80: 932-937. PMID: 4337277, DOI: 10.1016/s0022-3476(72)80004-0.Peer-Reviewed Original ResearchConceptsEBV antibodiesProspective studyLymphoblastoid cell linesAcutelymphoblastic leukemiaEpstein-Barr virus infectionAntibody-positive childrenAntibody-negative patientsEBV antibody titersAcute lymphoblastic leukemiaCourse of leukemiaCell linesEBV infectionInfectious mononucleosisUntreated patientsMaternal antibodiesCongenital leukemiaSerologic evidenceAntibody titersLymphoblastic leukemiaVirus infectionPatientsLeukemiaProgressive declineEBVUndetectable levels